Factors associated with concomitant psychotropic drug use in the treatment of major depression: A STAR*D report

CNS Spectrums

Volumn 14, Issue 9, 2009, Pages 487-498

  Shelton, Richard C ^a   Hollon, Steve D ^a   Wisniewski, Stephen R ^b   Alpert, Jonathan E ^c   Balasubramani, G K ^b   Friedman, Edward S ^d   Rush, A John ^e   Trivedi, Madhukar H ^e   Preskorn, Sheldon H ^f  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PSYCHOTROPIC AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ETHNICITY; FEMALE; FUNCTIONAL DISEASE; HUMAN; INCOME; INSOMNIA; MAJOR DEPRESSION; MALE; MARRIAGE; MENTAL FUNCTION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; QUALITY OF LIFE; SIDE EFFECT; SOCIAL STATUS; SUBSTANCE ABUSE; SUICIDAL IDEATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70849120686     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900023555     Document Type: Article

References (32)

1. Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654-661. (Pubitemid 38445509)
2. Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65:151-155.
3. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54:1395-1401. (Pubitemid 37220041)
4. Roeloffs CA, Wells KB, Ziedonis D, Tang L, Unutzer J. Problem substance use among depressed patients in managed primary care. Psychosomatics. 2002;405-412.
5. Goodwin GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol. 1997;11:115-122.
6. Landry MJ, Smith DE, Steinberg JR. Anxiety, depression, and substance use disorders: diagnosis, treatment, and prescribing practices. J Psychoactive Drugs. 1991;23:397-416.
7. Bingefors K, Isacson D, Von Knorring L, Smedby B, Ekselius L, Kupper LL. Antidepressant-treated patients in ambulatory care long-term use of non-psychotropic and psychotropic drugs. Br J Psychiatry. 1996;168:292-298. (Pubitemid 126442269)
8. Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:55-64.
9. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786-790.
10. Hales RE, Hilty DM, Brunson GH. Cost savings with nefazodone in treating depression. J Clin Psychiatry. 2002;63(Suppl 1):48-51.
11. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494.
12. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142. (Pubitemid 38230109)
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
14. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742-747. (Pubitemid 18189914)
15. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001;58:787-794. (Pubitemid 32717805)
16. Zimmerman M, Mattia JI. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry. 2001;42:175-189. (Pubitemid 32410920)
17. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73-82.
18. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-583. (Pubitemid 37289444)
19. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477-486.
20. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493-501.
21. Mundt JC. Interactive voice response systems in clinical research and treatment. Psychiatr Serv. 1997;48:611-612.
22. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233. (Pubitemid 126433231)
23. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326. (Pubitemid 23311543)
24. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461-464.
25. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
26. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71-79.
27. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
28. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxinei-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
29. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
30. Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ. Alcoholism and major depression in women. A twin study of the causes of comorbidity. Arch Gen Psychiatry. 1993;50:690-698. (Pubitemid 23263805)
31. Swendsen JD, Merikangas KR, Canino GJ, Kessler RC, Rubio-Stipec M, Angst J. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry. 1998;39:176-184. (Pubitemid 28326189)
32. Grant BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7:481-497.